IL17A and psoriasis: AS a first-class IL-17 inhibitor, Secukinumab was approved in the United States and Europe in 2016 for the treatment of diseases such as moderate to severe psoriasis, active AS, active psoriasis-arthritis, and axial spondyloarthritis.[42]